

Company Number: 55012

Crowley's Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Crowley's Pharmacy Limited
CONTENTS

	Page
Balance Sheet	3
Notes to the Financial Statements	4 - 8

Crowley's Pharmacy Limited

BALANCE SHEET

as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	7	419,023	438,774
Investments	8	2,500,392	5,008,556
Fixed Assets		2,919,415	5,447,330
Current Assets			
Stocks	9	138,000	172,000
Debtors	10	130,010	359,302
Cash and cash equivalents		2,185,800	954,273
		2,453,810	1,485,575
Creditors: amounts falling due within one year	11	(59,272)	(55,626)
Net Current Assets		2,394,538	1,429,949
Total Assets less Current Liabilities		5,313,953	6,877,279
Provisions for liabilities	12	(46,818)	(50,696)
Net Assets		5,267,135	6,826,583
Equity			
Called up share capital presented as equity		6,349	6,349
Retained earnings		5,260,786	6,820,234
Equity attributable to owners of the company		5,267,135	6,826,583

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Crowley's Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 13 February 2026 and signed on its behalf by:

Bridget Crowley
Director

Maura Crowley
Director

Crowley's Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Crowley's Pharmacy Limited is a company limited by shares incorporated in Ireland. 81 Main Street, Castleisland, Co. Kerry is the registered office, which is also the principal place of business of the company. The principal activity of the company is the operation of a pharmacy at Castleisland, Co. Kerry. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

Tangible assets and depreciation

Tangible fixed assets are initially stated at cost or at valuation and subsequently measured at cost, less accumulated depreciation and any impairment losses. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	2% Straight Line
Fixtures, fittings and equipment	-	12.5% Straight Line
Motor vehicles	-	20% Straight Line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Impairment

At each reporting date fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in profit or loss.

If an impairment loss subsequently reverses, the carry amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

Crowley's Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

Investments

Listed Investments

The company hold investments in non-puttable equitable shares in a company which is listed and actively traded on a recognised stock market. This investment is initially recorded at cost plus transaction costs. Thereafter it is valued at fair value which is the bid price of the securities in an active market at the reporting date.

Unlisted Investments

The company holds investments in unlisted non-puttable equity shares. This investment is initially recorded at cost plus transaction costs. Thereafter it is valued at fair value which is the value place on by BOI.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Provisions

Provisions are recognised when the company has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the same value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating (loss)/profit	2025	2024
	€	€
Operating (loss)/profit is stated after charging:		
Depreciation of tangible assets	25,034	24,373
	<u> </u>	<u> </u>

Crowley's Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

4. Income from investments		2025	2024	
		€	€	
Profit on disposal of investments		<u>33,444</u>	<u>-</u>	
5. Other Gains and Losses		2025	2024	
		€	€	
Fair value gains and losses are as follows:				
Investments in shares		<u>31,508</u>	<u>96,192</u>	
6. Employees				
The average monthly number of employees, including directors, during the financial year was 6, (2024 - 6).				
7. Tangible assets				
	Land and buildings freehold	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€	€
Cost or Valuation				
At 1 May 2024	542,800	81,930	53,800	678,530
Additions	-	5,283	-	5,283
At 30 April 2025	<u>542,800</u>	<u>87,213</u>	<u>53,800</u>	<u>683,813</u>
Depreciation				
At 1 May 2024	141,128	66,348	32,280	239,756
Charge for the financial year	10,856	3,418	10,760	25,034
At 30 April 2025	<u>151,984</u>	<u>69,766</u>	<u>43,040</u>	<u>264,790</u>
Net book value				
At 30 April 2025	<u>390,816</u>	<u>17,447</u>	<u>10,760</u>	<u>419,023</u>
At 30 April 2024	<u>401,672</u>	<u>15,582</u>	<u>21,520</u>	<u>438,774</u>
8. Investments				
		Listed investments	Other unlisted investments	Total
		€	€	€
Investments				
Cost or Valuation				
At 1 May 2024		5,773	5,002,783	5,008,556
Additions		1,000,000	-	1,000,000
Disposals		-	(3,500,000)	(3,500,000)
Revaluations		31,508	(39,672)	(8,164)
At 30 April 2025		<u>1,037,281</u>	<u>1,463,111</u>	<u>2,500,392</u>
Net book value				
At 30 April 2025		<u>1,037,281</u>	<u>1,463,111</u>	<u>2,500,392</u>
At 30 April 2024		<u>5,773</u>	<u>5,002,783</u>	<u>5,008,556</u>
9. Stocks		2025	2024	
		€	€	
Finished goods and goods for resale		<u>138,000</u>	<u>172,000</u>	

Crowley's Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

10. Debtors	2025	2024
	€	€
Trade debtors	68,196	322,650
Taxation	61,814	36,652
	<u>130,010</u>	<u>359,302</u>

All debtors are due within one year. All trade debtors are due within the company's normal debtors' terms, which is thirty days from the month. Trade debtors are shown net of impairment in respect of doubtful debts.

11. Creditors	2025	2024
Amounts falling due within one year	€	€
Trade creditors	25,350	23,119
Taxation	1,493	14,433
Directors' current accounts (Note 15)	20,559	6,874
Accruals	11,870	11,200
	<u>59,272</u>	<u>55,626</u>

The repayment terms of trade creditors vary between on demand and ninety days. No interest is payable on trade creditors.

Tax and social insurance are subject to the terms of the relevant legislation. Interest accrues on late payments at rates predetermined by the Revenue Commissioners. No interest was due at the financial year end date.

The terms of the accruals are based on the underlying contracts

12. Provisions for liabilities

The amounts provided for deferred taxation are analysed below:

	Investments	Total
	2025	2024
	€	€
At financial year start	50,696	-
Charged to profit and loss	(3,878)	50,696
At financial year end	<u>46,818</u>	<u>50,696</u>

13. Income Statement

	2025	2024
	€	€
At 1 May 2024	6,820,234	6,684,198
(Loss)/profit for the financial year	(1,559,448)	136,036
At 30 April 2025	<u>5,260,786</u>	<u>6,820,234</u>

14. Capital commitments

The Company had no material capital commitments at the year ended 30 April 2024.

Crowley's Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

15. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	44,690	72,982
Pension contributions	1,930,000	-
	<u>1,974,690</u>	<u>72,982</u>

The following amounts are repayable to the directors:

	2025	2024
	€	€
Bridget Crowley	<u>20,559</u>	<u>6,874</u>

16. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

17. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 13 February 2026.